Taysha Gene Therapies Share Holder Equity 2020-2025 | TSHA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies share holder equity from 2020 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Taysha Gene Therapies share holder equity from 2020 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.3B
Dr Reddy's Laboratories (RDY)	$11.8B
BridgeBio Pharma (BBIO)	$8.7B
Bausch Health Cos (BHC)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.9B
Amphastar Pharmaceuticals (AMPH)	$1B
Personalis (PSNL)	$494M
Assembly Biosciences (ASMB)	$137M
Sol-Gel Technologies (SLGL)	$35M
Evoke Pharma (EVOK)	$6M
Teligent (TLGT)	$0M